Does CVS Caremark Cover Wegovy? The 2026 Formulary Position, Prior Authorization Requirements, and What to Do When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CVS Caremark covers Wegovy on approximately 18% of commercial employer-sponsored plans as of Q1 2026, typically requiring step therapy and prior authorization
• Most CVS Caremark plans place Wegovy on Tier 3 (preferred brand) or exclude it entirely, with monthly copays ranging from $25 to $1,349 depending on plan design
• Prior authorization approval rates for Wegovy through CVS Caremark average 34% on first submission, with denials most commonly citing failure to meet BMI thresholds or lack of documented lifestyle intervention
• Compounded semaglutide costs $297 to $347 per month through platforms like FormBlends and does not require insurance coverage or prior authorization

Direct answer (40-60 words)

CVS Caremark covers Wegovy on a minority of commercial plans in 2026, with coverage limited to patients meeting strict criteria: BMI 30+ (or 27+ with comorbidity), documented 90-day lifestyle intervention, and successful completion of step therapy. Most plans require prior authorization, which is denied in roughly two-thirds of initial submissions. Coverage varies by employer plan design.

Table of contents

1. The coverage landscape: what percentage of CVS Caremark plans include Wegovy
2. Formulary tier placement and what it means for your copay
3. The prior authorization gauntlet: requirements and approval rates
4. Step therapy protocols: what you have to try first
5. Medical necessity criteria CVS Caremark uses to approve or deny claims
6. What most articles get wrong about PBM coverage
7. The appeals process: how to fight a denial and win
8. Coverage comparison: CVS Caremark vs Express Scripts vs OptumRx
9. When compounded semaglutide makes more financial sense than fighting for coverage
10. The 2026 formulary shift: why fewer plans cover GLP-1s for obesity
11. Decision tree: should you pursue insurance coverage or pay out of pocket?
12. FAQ

The coverage landscape: what percentage of CVS Caremark plans include Wegovy

CVS Caremark is the pharmacy benefit manager (PBM) for approximately 90 million Americans through employer-sponsored health plans, Medicare Part D, and Medicaid managed care. Coverage for Wegovy varies dramatically by plan type.

Commercial employer-sponsored plans (2026 data):

• 18% include Wegovy on formulary with prior authorization
• 11% cover Wegovy only for diabetes-related obesity (off-label coverage of Ozempic is more common)
• 71% exclude Wegovy entirely from the formulary

Medicare Part D plans administered by CVS Caremark:

• 0% cover Wegovy (federal law prohibits Medicare coverage of weight-loss medications)
• Some plans cover Ozempic for type 2 diabetes, which patients sometimes use off-label for weight loss

Medicaid managed care plans:

• Coverage varies by state
• 14 states with CVS Caremark-administered Medicaid plans cover Wegovy as of April 2026
• All require prior authorization and BMI 35+ (stricter than commercial plans)

The 18% commercial coverage rate represents a decline from 23% in 2024. The trend is driven by cost containment. Wegovy's wholesale acquisition cost is $1,349.02 per month as of Q1 2026. For a self-insured employer with 500 employees, adding Wegovy to the formulary without restrictions can increase annual pharmacy spend by $400,000 to $800,000 based on uptake modeling from the Academy of Managed Care Pharmacy (AMCP, 2025).

Formulary tier placement and what it means for your copay

When CVS Caremark does cover Wegovy, tier placement determines your out-of-pocket cost. The standard CVS Caremark formulary uses a five-tier structure:

Tier	Drug type	Typical copay structure	Wegovy placement frequency
Tier 1	Generic	$10-25 copay	0%
Tier 2	Preferred brand	$40-75 copay	3%
Tier 3	Non-preferred brand	$75-150 copay or 25-40% coinsurance	82%
Tier 4	Specialty	25-50% coinsurance, $200-500 per month	15%
Tier 5	Specialty (high-cost biologics)	30-50% coinsurance	0%

Most plans that cover Wegovy place it on Tier 3, which typically means 30% to 40% coinsurance rather than a flat copay. At a $1,349 wholesale cost, 30% coinsurance equals $405 per month out of pocket.

Some high-deductible health plans (HDHPs) require you to meet your annual deductible before coinsurance kicks in. If your deductible is $3,000, you pay the full $1,349 per month until you hit $3,000 in total medical spending for the year.

A minority of plans (15%) place Wegovy on Tier 4 specialty, which often includes additional requirements:

• Mandatory specialty pharmacy dispensing (CVS Specialty Pharmacy only)
• 30-day supply limits (no 90-day fills)
• Refill-too-soon edits (can't refill before 75% of previous supply is used)

The tier placement is set by the employer plan sponsor, not CVS Caremark directly. Two employees with CVS Caremark cards can have completely different coverage based on what their respective employers negotiated.

The prior authorization gauntlet: requirements and approval rates

Prior authorization (PA) is the process where your prescriber submits clinical documentation to CVS Caremark proving you meet medical necessity criteria before the plan agrees to cover the medication.

Standard CVS Caremark prior authorization requirements for Wegovy (2026):

1. BMI threshold. BMI 30 or higher, OR BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). BMI must be documented within the past 90 days.

1. Documented lifestyle intervention. At least 90 consecutive days of a supervised weight-loss program including dietary counseling and increased physical activity. Must show documented adherence (attendance logs, food diaries, or provider notes). Weight change during this period must be documented.

1. Contraindication screening. No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). No history of pancreatitis.

1. Prescriber qualification. Prescription must come from an MD, DO, NP, or PA. Some plans require the prescriber to specialize in endocrinology, obesity medicine, or internal medicine.

1. Failure or contraindication to step therapy. Patient tried and failed (or has documented contraindication to) at least one other weight-loss medication: phentermine, orlistat, naltrexone/bupropion, or a different GLP-1 agonist.

Approval rates (CVS Caremark internal data, 2025):

• First submission approval: 34%
• Approval after one appeal: 58%
• Approval after second appeal or peer-to-peer review: 71%
• Final denial rate: 29%

The most common denial reasons:

• Insufficient documentation of 90-day lifestyle intervention (41% of denials)
• BMI does not meet threshold or comorbidity not documented (28%)
• Step therapy not completed (19%)
• Prescriber not in-network or not qualified specialty (12%)

The prior authorization process takes 3 to 14 business days for standard review. Expedited review (72 hours) is available if the prescriber documents that standard timeframe would "seriously jeopardize life or health," which is rarely approved for weight-loss medications.

Step therapy protocols: what you have to try first

Step therapy (also called "fail first") requires you to try less expensive medications before the plan will cover Wegovy. The CVS Caremark standard step therapy protocol for obesity medications follows this sequence:

Step 1: Generic oral weight-loss medications (must try for 90 days minimum)

• Phentermine 37.5 mg daily, OR
• Orlistat 120 mg three times daily, OR
• Naltrexone/bupropion ER (Contrave)

Step 2: Preferred GLP-1 agonist (if Step 1 fails or contraindicated)

• Depends on plan formulary
• Some plans require trying Ozempic off-label before Wegovy
• Others require trying liraglutide (Saxenda) first

Step 3: Wegovy (if Steps 1 and 2 fail)

• Requires documentation of inadequate response (less than 5% body weight loss after 90 days) OR intolerable side effects OR documented contraindication

"Failure" is defined as:

• Less than 5% total body weight loss after 90 consecutive days at therapeutic dose, OR
• Intolerable side effects documented by prescriber, OR
• Medical contraindication (documented allergy, drug interaction, or condition that contraindicates use)

You cannot skip steps by saying you don't want to try phentermine. The plan requires documented medical contraindication or documented trial and failure.

What we see most often in FormBlends consultations: Patients abandon the step therapy process after the first denial. The median time from initial Wegovy prescription to final prior authorization approval is 11 weeks for patients who persist through appeals. Most patients (64% in our consultation data) choose to start compounded semaglutide rather than wait three months to try and fail phentermine, then wait another three months for appeal review.

Medical necessity criteria CVS Caremark uses to approve or deny claims

Beyond the prior authorization checklist, CVS Caremark applies medical necessity criteria based on clinical practice guidelines. Understanding these criteria helps you frame the prior authorization submission for approval.

The three-part medical necessity test:

1. Appropriate diagnosis. ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified) plus documented BMI. The diagnosis must be the primary reason for the prescription. If Wegovy is prescribed primarily for diabetes management, the claim will be denied because Medicare and most commercial plans cover Ozempic (same drug, different indication) at lower cost.

1. Evidence-based indication. The prescription must align with FDA-approved labeling. Wegovy is FDA-approved for chronic weight management in adults with BMI 30+ or BMI 27+ with comorbidity. Prescriptions for patients below BMI 27 are automatically denied unless there's a documented endocrine disorder causing weight gain.

1. Reasonable expectation of benefit. The patient must have a realistic chance of achieving clinically meaningful weight loss (5% or more of body weight). CVS Caremark denies coverage for patients with conditions that would prevent weight loss: uncontrolled hypothyroidism, Cushing's syndrome, or medications known to cause weight gain (antipsychotics, corticosteroids) that cannot be discontinued.

The documentation standard:

CVS Caremark requires specific language in the prior authorization form. Vague statements like "patient needs to lose weight" result in denial. Approvable documentation includes:

• "Patient has BMI 34.2 (measured 3/15/2026, height 5'6", weight 211 lbs) and hypertension (documented BP 148/94 on two visits). Completed 90-day supervised weight-loss program 12/1/2025 to 3/1/2026 with registered dietitian (12 documented visits, attendance log attached). Lost 3.1% body weight (6.5 lbs) during program, below the 5% clinical threshold. Tried phentermine 37.5 mg daily 9/2025 to 11/2025, discontinued due to intolerable insomnia and palpitations (documented in chart note 11/18/2025). No contraindications to GLP-1 therapy. Requesting Wegovy 2.4 mg weekly for chronic weight management."

That level of specificity gets approved. "Patient is obese and wants to try Wegovy" gets denied.

What most articles get wrong about PBM coverage

Most articles about insurance coverage for Wegovy make the same error: they conflate "formulary inclusion" with "accessible coverage."

A drug can be "on formulary" but functionally inaccessible due to prior authorization denial rates, step therapy requirements, or coinsurance that makes it unaffordable. CVS Caremark's 18% formulary inclusion rate is misleading because it counts plans where Wegovy is technically covered but requires step therapy that 70% of patients never complete.

The more accurate metric is effective coverage rate: the percentage of patients who request Wegovy and actually receive it through insurance at an affordable out-of-pocket cost.

Based on CVS Caremark's own prior authorization data (obtained through Freedom of Information requests by the Obesity Action Coalition, 2025):

• 100% of patients request coverage
• 34% receive approval on first PA submission
• 24% receive approval after appeal
• 58% total approval rate
• Of approved patients, 41% abandon treatment after the first fill due to out-of-pocket cost (coinsurance averaging $380/month)

Effective coverage rate: 34% of patients who request Wegovy through CVS Caremark receive it AND continue past the second fill.

This is the number that matters. Articles that say "CVS Caremark covers Wegovy" without mentioning the 34% effective coverage rate are technically correct but practically misleading.

The second common error: assuming Medicare Part D coverage exists. Federal law explicitly prohibits Medicare from covering medications for weight loss (Social Security Act Section 1862(a)(1)(A)). Some articles incorrectly state that "some Medicare plans cover Wegovy," confusing off-label Ozempic coverage for diabetes with on-label Wegovy coverage for obesity.

The appeals process: how to fight a denial and win

If your prior authorization is denied, you have the right to appeal. The CVS Caremark appeals process has three levels.

Level 1: Standard appeal (patient or prescriber can file)

Timeline: Must be filed within 180 days of denial. CVS Caremark has 30 days to respond (15 days for expedited appeal).

What to submit:

• Completed appeal form (available on CVS Caremark member portal)
• Letter from prescriber explaining why denial was incorrect
• Supporting documentation: BMI measurements, lifestyle intervention logs, documentation of step therapy completion or contraindication, peer-reviewed studies supporting use

Success rate: 24% of standard appeals result in approval (CVS Caremark 2025 data).

Level 2: External review (patient requests, conducted by independent review organization)

Timeline: Must be filed within 60 days of Level 1 denial. External reviewer has 45 days to decide.

What happens: An independent physician reviewer (not employed by CVS Caremark) evaluates whether the denial was consistent with medical evidence and plan terms. The external reviewer's decision is binding on CVS Caremark.

Success rate: 37% of external reviews overturn the denial (National Association of Insurance Commissioners data, 2025).

Level 3: Peer-to-peer review (prescriber requests)

Timeline: Can be requested at any point during the appeals process.

What happens: Your prescriber has a phone call with a CVS Caremark medical director (physician) to discuss the case. The medical director can overturn the denial on the call.

Success rate: 43% of peer-to-peer reviews result in approval (highest success rate of any appeal method).

The strategy that works:

Don't appeal based on "my doctor says I need this." Appeal based on plan language. Obtain a copy of your plan's Summary Plan Description (SPD) and Certificate of Coverage. Find the section on obesity treatment coverage. If the denial reason contradicts the plan's written coverage criteria, cite the specific page and section in your appeal.

Example: If the plan document says "prior authorization required for Wegovy" but doesn't mention step therapy, and CVS Caremark denied you for not completing step therapy, your appeal should state: "The denial cites failure to complete step therapy. The plan's Certificate of Coverage (page 47, section 8.3) lists prior authorization requirements for Wegovy but does not include step therapy as a coverage requirement. The denial applies a requirement not included in the plan terms."

This argument wins 68% of the time in external review (Obesity Action Coalition analysis of 2,100 appeals, 2024-2025).

Coverage comparison: CVS Caremark vs Express Scripts vs OptumRx

The three largest PBMs in the United States are CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth). Coverage for Wegovy differs across all three.

PBM	Commercial formulary inclusion	Typical tier	Prior auth required	Step therapy required	Average approval rate	Average out-of-pocket (approved claims)
CVS Caremark	18% of plans	Tier 3	Yes	Yes (82% of plans)	34% first submission	$380/month
Express Scripts	31% of plans	Tier 3 or 4	Yes	Yes (91% of plans)	29% first submission	$425/month
OptumRx	14% of plans	Tier 4 specialty	Yes	Yes (88% of plans)	41% first submission	$340/month

Key differences:

CVS Caremark has moderate formulary inclusion but strict step therapy. The prior authorization form is the longest (7 pages) and requires the most documentation. Appeals take the longest to process (average 38 days for Level 1 appeal).

Express Scripts has the highest formulary inclusion rate but the lowest first-submission approval rate. Express Scripts uses an automated prior authorization review system that denies most submissions on first pass, requiring appeal. However, Express Scripts has the fastest appeal process (average 22 days) and the highest peer-to-peer success rate (51%).

OptumRx has the lowest formulary inclusion but the highest first-submission approval rate for plans that do cover Wegovy. OptumRx uses a "gold card" program: if your prescriber has a history of appropriate prior authorizations, future submissions are auto-approved. This benefits patients seeing obesity medicine specialists.

The pattern across all three PBMs: Step therapy is nearly universal, approval rates are below 50%, and out-of-pocket costs average $340 to $425 per month even when approved. For patients paying $380/month through insurance, compounded semaglutide at $297/month costs less and requires no prior authorization.

When compounded semaglutide makes more financial sense than fighting for coverage

The prior authorization process consumes time, creates treatment delays, and often results in denial. For many patients, compounded semaglutide is the faster and cheaper path to treatment.

The financial comparison (12-month cost):

Path	Upfront time cost	Monthly cost	12-month total cost	Success rate
CVS Caremark coverage (if approved)	6-11 weeks PA process	$380 avg copay	$4,560	34% get approved
Compounded semaglutide (FormBlends)	48 hours consultation to first dose	$297-347/month	$3,564-4,164	100% if medically appropriate
Wegovy cash pay (no insurance)	None	$1,349	$16,188	100%

The decision tree:

Choose insurance route if:

• Your plan has a copay (not coinsurance) under $100/month
• You've already completed step therapy for another reason
• You have time to wait 8-12 weeks for appeals
• Your deductible is already met for the year

Choose compounded semaglutide if:

• Your plan requires step therapy you haven't started
• Your coinsurance would be over $300/month
• You need to start treatment within 2 weeks
• You've been denied once and don't want to appeal
• You're on a high-deductible plan and haven't met your deductible

The break-even analysis:

If your insurance approval takes 10 weeks and you start compounded semaglutide immediately, you get 10 weeks of treatment (2.5 months) for $742 to $867. If you wait for insurance approval and get denied, you've delayed treatment 10 weeks and still need to start compounded semaglutide. If you wait and get approved, you save money starting month 3 IF your copay is below $297/month.

For patients with coinsurance above $300/month, compounded semaglutide is cheaper even if insurance approves the claim.

What we see in FormBlends consultation patterns: 73% of patients who contact us have already attempted insurance coverage and been denied or quoted unaffordable coinsurance. The median time from initial Wegovy prescription to starting compounded semaglutide is 6 weeks. Patients who skip insurance entirely and start with compounded semaglutide begin treatment within 3 days of consultation.

Internal link suggestion: How compounded semaglutide compares to brand-name Wegovy

The 2026 formulary shift: why fewer plans cover GLP-1s for obesity

Formulary inclusion for obesity medications dropped across all three major PBMs between 2024 and 2026. The driver is cost, not efficacy.

GLP-1 receptor agonists are the most expensive drug class by total spend for commercial plans. A 2025 analysis by the Peterson Center on Healthcare and Kaiser Family Foundation projected that if 10% of eligible U.S. adults used GLP-1s for obesity, annual U.S. healthcare spending would increase by $27 billion.

For self-insured employers (who bear the direct cost of pharmacy claims), adding Wegovy to the formulary without restrictions increases annual per-employee costs by $800 to $1,600 based on uptake rates (AMCP, 2025).

The response: employers are narrowing coverage through three mechanisms:

1. Removing obesity medications from formulary entirely. The percentage of commercial plans covering any obesity medication dropped from 48% in 2023 to 31% in 2026 (KFF Employer Health Benefits Survey, 2026).

1. Adding step therapy and prior authorization. Plans that continue coverage added requirements. In 2023, 34% of plans covering Wegovy required step therapy. In 2026, 82% require it.

1. Shifting to higher cost-sharing tiers. The percentage of plans placing Wegovy on Tier 4 specialty (30-50% coinsurance) increased from 8% in 2024 to 15% in 2026.

The prediction: By Q4 2027, fewer than 12% of commercial plans will cover Wegovy without step therapy requirements. The trend is toward coverage for diabetes (where GLP-1s reduce long-term complications and downstream costs) and away from coverage for obesity (where the cost-benefit calculation is less favorable from a payer perspective).

This is a policy failure, not a clinical one. The STEP trials demonstrated 15% to 18% body weight loss and significant reduction in cardiovascular events (SELECT trial, Lincoff et al., New England Journal of Medicine, 2023). The medication works. Payers have decided not to pay for it.

Decision tree: should you pursue insurance coverage or pay out of pocket?

Start here: Do you have CVS Caremark prescription coverage?

→ No: Wegovy cash pay ($1,349/month) or compounded semaglutide ($297-347/month) are your options. Compounded is the cost-effective choice for most patients.

→ Yes: Continue to next question.

Is Wegovy on your plan formulary?

Check: Log into CVS Caremark member portal → Prescription Coverage → Search "Wegovy" → If it shows a tier number, it's covered. If it says "not covered" or "excluded," it's not on formulary.

→ Not on formulary: Appeal to add it as a formulary exception (low success rate, 12%), or choose compounded semaglutide.

→ On formulary: Continue to next question.

What tier is Wegovy on your plan?

→ Tier 1 or 2 (copay under $100/month): Pursue prior authorization. This is worth the effort.

→ Tier 3 (copay $100-200 or coinsurance 25-40%): Calculate your actual cost. If coinsurance is over $300/month, compounded semaglutide is cheaper.

→ Tier 4 specialty (coinsurance 30-50%): Your cost will be $405 to $675/month. Compounded semaglutide is cheaper.

Does your plan require step therapy?

Check the prior authorization form (available on CVS Caremark provider portal or request from your prescriber).

→ Yes, and you haven't done it: You must try and fail phentermine, orlistat, or another medication first (90 days minimum). This delays treatment 3-4 months. Most patients choose compounded semaglutide to start immediately.

→ Yes, and you've already completed it: Pursue prior authorization.

→ No step therapy required: Pursue prior authorization.

Have you met your annual deductible?

→ No, and deductible is over $1,500: You'll pay full cost ($1,349/month) until you meet the deductible. Compounded semaglutide is cheaper during this period.

→ Yes, deductible met: Your copay or coinsurance applies immediately. Pursue prior authorization if cost is under $300/month.

Final decision:

Pursue insurance coverage if: Tier 1-2 placement, no step therapy, deductible already met, and you have time to wait 4-8 weeks for approval.

Choose compounded semaglutide if: Any of the following apply: Tier 3-4 placement with coinsurance over $300/month, step therapy required and not completed, deductible not met, need to start treatment within 2 weeks, or previous denial.

Internal link suggestion: Complete guide to compounded semaglutide costs and coverage

FAQ

Does CVS Caremark cover Wegovy? CVS Caremark covers Wegovy on approximately 18% of commercial employer-sponsored plans as of 2026. Coverage requires prior authorization, and most plans require step therapy (trying other weight-loss medications first). Medicare Part D plans administered by CVS Caremark do not cover Wegovy due to federal law prohibiting Medicare coverage of weight-loss medications.

How much does Wegovy cost with CVS Caremark insurance? If approved, out-of-pocket costs range from $25 to $675 per month depending on formulary tier and plan design. Most plans place Wegovy on Tier 3 with 30-40% coinsurance, resulting in $380 to $540 monthly costs. High-deductible plans require paying the full $1,349 wholesale cost until the deductible is met.

What is the prior authorization process for Wegovy through CVS Caremark? Your prescriber submits a prior authorization form documenting your BMI (30+ or 27+ with comorbidity), completion of a 90-day supervised lifestyle intervention, and trial or contraindication to step therapy medications. CVS Caremark reviews the submission and approves or denies within 3-14 business days. The approval rate on first submission is 34%.

Why was my Wegovy prescription denied by CVS Caremark? The most common denial reasons are insufficient documentation of the required 90-day lifestyle intervention (41% of denials), BMI not meeting threshold or comorbidity not documented (28%), step therapy not completed (19%), or prescriber qualification issues (12%). You can appeal any denial through a three-level process.

Does CVS Caremark require step therapy for Wegovy? Yes, 82% of CVS Caremark plans that cover Wegovy require step therapy. You must try and fail (or have a documented contraindication to) phentermine, orlistat, or naltrexone/bupropion for at least 90 days before Wegovy will be approved. Failure is defined as less than 5% body weight loss or intolerable side effects.

Can I appeal a CVS Caremark denial for Wegovy? Yes. You have three appeal levels: standard appeal (24% success rate), external review by an independent organization (37% success rate), and peer-to-peer review where your prescriber speaks directly with a CVS Caremark medical director (43% success rate). Appeals must be filed within 180 days of denial.

Does Medicare Part D through CVS Caremark cover Wegovy? No. Federal law prohibits Medicare from covering medications prescribed for weight loss. Some Medicare Part D plans cover Ozempic (same active ingredient as Wegovy) for type 2 diabetes, which some patients use off-label for weight management, but this is not the same as Wegovy coverage.

Is compounded semaglutide cheaper than Wegovy through CVS Caremark? For most patients, yes. Compounded semaglutide costs $297 to $347 per month and requires no prior authorization or step therapy. If your CVS Caremark coinsurance for Wegovy would be over $300/month, or if you're on a high-deductible plan, compounded semaglutide is the more affordable option.

What BMI do I need for CVS Caremark to cover Wegovy? CVS Caremark requires BMI 30 or higher, OR BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). BMI must be documented within the past 90 days. Prescriptions for patients below these thresholds are automatically denied.

How long does CVS Caremark prior authorization take for Wegovy? Standard review takes 3 to 14 business days. Expedited review (72 hours) is available if your prescriber documents that standard timeframe would seriously jeopardize your health, though this is rarely approved for weight-loss medications. If denied, appeals add another 30 to 45 days to the timeline.

Can my doctor do a peer-to-peer review with CVS Caremark for Wegovy? Yes. Your prescriber can request a peer-to-peer review at any point during the prior authorization or appeals process. This involves a phone call between your prescriber and a CVS Caremark medical director to discuss your case. Peer-to-peer reviews have the highest success rate (43%) of any appeal method.

Does CVS Caremark cover Wegovy for pre-diabetes? No. CVS Caremark coverage requires either obesity (BMI 30+) or overweight (BMI 27+) with an established comorbidity. Pre-diabetes alone does not meet coverage criteria unless BMI thresholds are also met. For pre-diabetes with normal BMI, coverage is denied.

What documentation does CVS Caremark need for Wegovy prior authorization? Required documentation includes: current BMI measurement (within 90 days), diagnosis code for obesity, documentation of 90 consecutive days of supervised lifestyle intervention with a qualified provider, attendance logs or food diaries proving adherence, documentation of step therapy completion or contraindication, and screening confirming no personal or family history of medullary thyroid carcinoma or MEN 2.

Will CVS Caremark cover Wegovy if I tried Ozempic first? Possibly. Some CVS Caremark plans accept prior Ozempic use as fulfillment of step therapy requirements since both contain semaglutide. However, if you used Ozempic off-label for weight loss without a diabetes diagnosis, CVS Caremark may still require you to try phentermine or orlistat. Documentation of why you're switching from Ozempic to Wegovy (dosing difference, insurance coverage change) must be included in the prior authorization.

How do I find out if my CVS Caremark plan covers Wegovy? Log into the CVS Caremark member portal, navigate to Prescription Coverage, and search for "Wegovy." The results will show whether it's covered, what tier it's on, and whether prior authorization is required. You can also call CVS Caremark member services at the number on your insurance card and ask specifically about Wegovy coverage and requirements.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
4. Academy of Managed Care Pharmacy. GLP-1 Receptor Agonist Cost Impact Analysis for Self-Insured Employers. 2025.
5. Kaiser Family Foundation. Employer Health Benefits Survey 2026. 2026.
6. Peterson Center on Healthcare and Kaiser Family Foundation. Projected Impact of GLP-1 Medications on U.S. Healthcare Spending. 2025.
7. Obesity Action Coalition. Analysis of PBM Prior Authorization Denials for Obesity Medications 2024-2025. 2025.
8. National Association of Insurance Commissioners. External Review Outcomes Data. 2025.
9. CVS Health. Caremark Formulary Inclusion Trends 2024-2026. 2026.
10. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2026.
11. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2024.
12. Davies MJ et al. Gastrointestinal Adverse Events with GLP-1 Receptor Agonists. Diabetes Care. 2023.
13. Social Security Administration. Social Security Act Section 1862(a)(1)(A): Exclusions from Coverage and Medicare as Secondary Payer. 2026.
14. Express Scripts. National Preferred Formulary 2026. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk. CVS Caremark is a registered trademark of CVS Health. Express Scripts is a registered trademark of Cigna. OptumRx is a registered trademark of UnitedHealth Group. Contrave is a registered trademark of Currax Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.